Login to Your Account



Immunocellular chases positive survival outcome in new SPA-governed phase III

By Michael Fitzhugh
Staff Writer

Thursday, August 13, 2015

Reviving hopes for its experimental dendritic cell-based vaccine, ICT-107, Immunocellular Therapeutics Ltd. said it expects to soon begin enrolling newly diagnosed glioblastoma patients in a registrational phase III trial under an SPA freshly agreed with the FDA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription